 Two clinical studies including interventional RaDaRTM study FT. MYERS, FL ACCESSWIRE October 19, 2021 NeoGenomics, Inc. NASDAQ:NEO, a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited Inivata has entered into a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivatas liquid biopsy assays, InVisionFirst-Lung and RaDaRTM in two separate studies. 